Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

By C. Grob, A. Danforth, G. S. Chopra, M. Hagerty, C. McKay, A. Halberstadt, G. Greer. Archives of General Psychiatry, 2011

1,099 citations recorded by the source corpus.

Subfields: Clinical Psychology, Cognitive Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/78d83913bd0ce1c438a35ea795b0c4182ba005fa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Cognitive Neuroscience

In Pharmacology

Citations in the corpus

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, methodology): “Building upon hallucinogen research with cancer patients from over four decades ago, two recently published randomized controlled trials (RCTs) with serotoninergic psychedelics to treat cancer-related psychological distress, one using psilocybin in patients with advanced-stage cancer conducted at Ha”
Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects (2011, methodology): “Death Transcendence Scale: The 26-item Death Transcendence Scale (Hood and Morris 1983; VandeCreek 1999) was administered because a potentially important clinical application of psilocybin is in treatment of individuals who are anxious or depressed in response to terminal illness (Grob et al. 2011).”
The Varieties of Self-Transcendent Experience (2017, background): “, & Haidt, J. (2009). Witnessing excellence in action: The “other-praising” emotions of elevation, gratitude, and admiration. The Journal of Positive Psychology, 4, 105–127. http://dx.doi.org/10.1080/ 17439760802650519 Algoe, S. B., Haidt, J., & Gable, S. L. (2008). Beyond reciprocity: Gratitude and”
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction (2014, background): “Consistent with previous findings (Griffiths et al., 2006; Grob et al., 2011), blood pressure and heart rate were elevated during drug effects, with peak values occurring on average between 1.5 and 2.5 hours post-psilocybin administration.”
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. (2016, background): “…cantly decreased anxiety and depression scores were observed 3 and 6 months after a single dose of psilocybin in patients with anxiety related to end-stage cancer, 15 and improve ments in wellbeing lasting for more than 1 year were observed in healthy individuals given a single dose of psilocybin.”
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (2012, methodology): “Posterior cingulate cortex 1.64 0.51 Superior temporal cortex 1.59 0.53 Medial inferior temporal cortex 1.57 0.52 Dorsolateral prefrontal cortex (DLPFC) 1.51 0.52 Anterior cingulate cortex 1.49 0.54 Medial inferior frontal gyrus 1.49 0.50 Occipital cortex 1.47 0.47 Orbitofrontal cortex 1.46 0.54 Par”
Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness (2011, background): “Clinical work along these lines was initiated in the 1950s and suggested possible improvements after hallucinogen treatment in individuals with terminal cancer (Grob et al., 2011; Kast, 1967; Richards et al., 1977) and substance dependence (Halpern, 1996; Mangini, 1998; Terrill et al.”
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “Re-latedly, psychedelics appear to induce a regressive state, both behaviorally (Grof, 1979) and in terms of brain function (Roseman et al., 2014; Carhart-Harris et al., 2016c).”
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases (2014, methodology): “In view of promising historical studies with adjunctive LSD treatment in this population and a recent promising study using psilocybin (Grob et al., 2011), as well as the urgent need for more effective treatments of anxiety in these participants, further study is warranted into the potential of LSD-”
Serotonin and brain function: a tale of two receptors (2017, background): “…2015b; Muthukumaraswamy et al., 2013) and clinical trials (Bogenschutz et al., 2015; Carhart-Harris et al., 2016a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Mithoefer et al., 2011; Ross et al., 2016; Sanches et al., 2016) – see Carhart-Harris and Goodwin (2017) for a review.”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “The results substantially extend the findings of a recent double-blind pilot study with a lower dose of psilocybin (14 mg/70 kg) in cancer patients that showed non-significant trends for benefits of psilocybin compared with placebo (niacin) on measures of depression and anxiety, with some significan”
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “…compulsive disorder (Moreno et al, 2006), psilocybin, and LSD for end-of-life psychological distress (Gasser et al, 2014; Griffiths et al, 2016; Grob et al, 2011; *Correspondence: Dr RL Carhart-Harris, Psychedelic Research Group, Centre for Psychiatry, Division of Brain Sciences, Faculty of…”
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017, background): “…separate trials have reported improvements in depressive symptoms after psilocybin-assisted psychotherapy (Griffiths et al. 2016; Ross et al. 2016; Grob et al. 2011; CarhartHarris et al. 2016), including one in which ‘treatment-resistant depression’ was the primary criterion for inclusion…”
Developing Guidelines and Competencies for the Training of Psychedelic Therapists (2017, background): “, 2014) and for Heffter, psilocybin for the treatment of anxiety in patients with advancedstage cancer (Grob et al., 2011).”
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study (2015, positive): “The past decade has seen a rapid growth of interest in potential clinical applications of the classic hallucinogen psilocybin (Bogenschutz, 2012; Burdick and Adinoff, 2013; Carhart-Harris et al., 2012, 2013; Garcia-Romeu et al., 2013; Grob et al., 2011; Kometer et al., 2012; Nichols, 2014).”
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014, background): “…that had a lasting beneﬁcial impact on subjective well-being (Grifﬁths et al., 2006, 2008) and a moderate single dose of psilocybin administered to patients with advanced-stage cancer signiﬁcantly reduced anxiety and depression scores for months after the acute experience (Grob et al., 2011).”
Psychedelics Promote Structural and Functional Neural Plasticity (2018, background): “Like ketamine, serotonergic psychedelics and entactogens have demonstrated rapid and long-lasting antidepressant and anxiolytic effects in the clinic after a single dose (Bouso et al., 2008; Carhart-Harris and Goodwin, 2017; Grob et al., 2011; Mithoefer et al., 2013, 2016; Nichols et al., 2017; Sanc”